A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. Hepatera is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC - Russia's government fund of venture capital funds. Hepatera was founded in 2011 with the goal of developing and launching innovative therapeutics for treatment of liver diseases into the Russian market.
Hepatera is developing an innovative drug candidate - Myrcludex B - for treatment of chronic viral hepatitis B and D in close cooperation with the German biotech company MYR GmbH, a portfolio company of High-Tech Gruenderfonds (HTGF), one of Europe's largest venture funds.
The objectives of the ongoing Phase IIa clinical trial are to study safety and tolerability, as well as efficacy of several dose levels of Myrcludex B in comparison to standard therapy (nucleoside analogues). One specific aim is to study efficacy parameters not influenced by the standard therapy in the majority of cases.
Preliminary results are expected in June 2014 and will be presented at international specialized conferences.
Dr. Alexander Alexandrov (Medical Director, MYR GmbH): "Introduction of potentially curative therapies for chronic HBV infection is awaited by the patients for a long time. We look forward to the evaluation of the results of this study which might become a significant step on the path of creating a new tool in treatment of this important disease".
Chronic viral hepatitis B (CHB) is one of the major problems facing healthcare systems globally. According to the World Health Organization, the prevalence of hepatitis B virus infection (HBV) worldwide is very high with about 350 million of them chronically infected. The market for chronic hepatitis B therapy is constantly growing, with significant unfulfilled demand for new therapies due to the lack of curative treatment options.
Prof. Stephan Urban (University Hospital Heidelberg), originator of the technology: "The enrollment of all planned patients into this trial is a very significant milestone for the drug; the success of the molecule can change treatment standards of chronic viral hepatitis B".
Link : http://www.prnewswire.com/news-releases/maxwell-biotech-venture-funds-portfolio-company-hepatera-completes-enrollment-of-phase-iia-clinical-trial-of-myrcludex-b-for-hbv-248734041.html
Hi, thanks for sharing. Myrcludex-B prevents viral replication. According to scientific studies done, Myrcludex-B efficiently not only prevented HBV spreading from infected human hepatocytes in vivo, but also hindered amplification of the cccDNA pool in initially infected hepatocytes. Regards.
So would it have a similar function to REP9AC' In terms of rapidly taking surface antigen out of the blood? Because it would be nice and more fair to see something similar reach the market sooner rather than later due to the fact
life long/ long term aren't really in us the patients best interests
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.